Business Wire

Xylem Acquires Majority Stake in Idrica to Empower Water Utilities With Intelligent Solutions

10.12.2024 13:15:00 CET | Business Wire | Press release

Share

Companies will further integrate solutions that help utilities accelerate digitalization and tackle critical challenges such as water scarcity and aging infrastructure

Global water solutions company Xylem (NYSE: XYL) today announced that it has acquired a majority stake in Idrica, a leader in water data management and analytics, to empower water utilities with intelligent solutions for their most critical challenges.

Xylem Vue, which combines Xylem’s existing digital water solutions portfolio with Idrica’s technology platform, empowers customers to address critical challenges such as water scarcity and aging infrastructure with real-time insights. Today’s move will enable the two companies to further integrate their solutions and create a simpler, more powerful customer experience.

“Deepening our partnership with Idrica is a critical piece of our strategy to deliver intelligent solutions to our customers,” said Matthew Pine, CEO of Xylem. “Together, we can help them see deeper into their networks and use insights to solve long-standing problems like water loss more effectively and affordably than ever before.”

According to Jaime Barba, CEO of Idrica and head of Xylem Vue, “Every day, water utilities are challenged by complex systems that make it difficult to use data to make decisions. Our deeper partnership will further enable water and wastewater utilities to connect and manage their digital assets and streamline operations in a simple, secure and holistic view.”

Over the past year and a half, water utilities worldwide have deployed the Xylem Vue integrated software and analytics platform to optimize their infrastructure, lower costs, and adapt to new conditions.

For example, the City of Hot Springs, Arkansas, improved its operations by adding virtual district metering areas using Xylem Vue. The integrated software and analytics platform enabled the city to pinpoint high water loss areas by creating smaller, more manageable zones within the network. By deploying these advanced digital solutions, Hot Springs reduced non-revenue water loss by nearly 50%.

Another example is the city of Monterrey, Mexico. Servicios de Agua y Drenaje de Monterrey, I.P.D. (SADM), which serves a metropolitan area of 5.3 million people, sought a digital solution to monitor severe drought conditions and enhance efficiency.

Xylem Vue enabled SADM to implement smart monitoring and management of water pressure, flow and consumption. The platform also helps the utility identify potential anomalies that point to visible and hidden leaks. As a result, SADM has realized overall water savings of 17% – and up to 37% in certain key sections of pipeline – significantly increasing its operational efficiency and management.

About Xylem

Xylem (XYL) is a Fortune 500 global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered combined pro forma revenue of $8.1 billion in 2023, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and Let’s Solve Water.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210980286/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye